Vertex Rejects England’s Orkambi Offer
Vertex has rejected the “final offer” put forward by the National Health Service in England for its cystic fibrosis drugs, including Orkambi. The company’s chief executive wants a meeting with the head of the NHS.
You may also be interested in...
The NHS in England says it has made a “revised and improved” offer to Vertex to make Orkambi available, but the company is not impressed and says its attitude to the negotiations has been mischaracterized.
The UK government has criticized Vertex for the company’s approach to pricing its cystic fibrosis drug Orkambi. In the meantime, a parliamentary inquiry that could expose sensitive pricing details moves forward.
Vertex’s portfolio-based access deal in Denmark will give patients quicker access to a range of cystic fibrosis drugs and give budget predictability to the company and government.